- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Novartis Told to Revise Protocol, Justify Sample Size in ITU512 Clinical Trial Proposal

New Delhi: Novartis Healthcare Private Limited has been directed by the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organisation (CDSCO) to submit additional data and protocol clarifications for its proposed Phase I/II clinical study on ITU512, an investigational therapy for hemoglobin-related disorders.
The proposal was discussed during the 08th SEC (Haematology) meeting held on 15th July 2025 at CDSCO headquarters, New Delhi. Novartis presented Protocol No.CITU512A12101, Version 01, dated 29 July 2024.
ITU512 is believed to be an advanced therapeutic candidate potentially targeting sickle cell disease or β-thalassemia by modulating fetal hemoglobin levels. However, the SEC raised several scientific and protocol design concerns that require resolution before trial approval.
According to the committee, the primary endpoint must be clearly specified in terms of fetal hemoglobin (HbF) increase >15%, and this threshold must be scientifically justified based on prior studies, regulatory benchmarks, or clinical relevance. The panel also requested a justification for including patients with an absolute fetal hemoglobin percentage <15%.
During the presentation, SEC noted that definitions of the primary and secondary endpoints were not aligned with the submitted protocol. The committee emphasized that the criteria for efficacy evaluation should be explicitly defined. Further, exploratory endpoints such as vaso-occlusive crisis (VOCs) events must be incorporated into the initial protocol design.
Additionally, the firm was asked to submit Phase I data, including safety and hemolysis profiles, from either the current study or any other country where ITU512 has been tested. A detailed justification for the proposed sample size and dosing regimen was also requested.
“Accordingly, the firm shall submit the response for further review by committee,” the SEC recommended.
M. Pharm (Pharmaceutics)
Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751